Bonaque Juan C, Pascual-Figal Domingo A, Manzano-Fernández Sergio, González-Cánovas Cristina, Vidal Alfredo, Muñoz-Esparza Carmen, Garrido Iris P, Pastor-Pérez Francisco, Valdés Mariano
Servicio de Cardiología, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain.
Rev Esp Cardiol (Engl Ed). 2012 Jul;65(7):606-12. doi: 10.1016/j.recesp.2011.12.006. Epub 2012 Mar 21.
Red blood cell distribution width has emerged as a new prognostic biomarker in cardiovascular diseases. Its additional value in risk stratification of patients with chronic heart failure has not yet been established.
A total of 698 consecutive outpatients with chronic heart failure were studied (median age 71 years [interquartile range, 62-77], 63% male, left ventricular ejection fraction 40 [14]%). On inclusion, the red cell distribution width was measured and clinical, biochemical, and echocardiographic variables were recorded. The median follow-up period was 2.5 years [interquartile range 1.2-3.7].
A total of 211 patients died and 206 required hospitalization for decompensated heart failure. Kaplan-Meier analysis showed an increase in the probability of death and hospitalization for heart failure with red cell distribution width quartiles (log rank, P<.001). A ROC analysis identified a red cell distribution width of 15.4% as the optimal cut-off point for a significantly higher risk of death (P<.001; hazard ratio=2.63; 95% confidence interval, 2.01-3.45) and hospitalization for heart failure (P<.001; hazard ratio=2.37; 95% confidence interval, 1.80-3.13). This predictive value was independent of other covariates, and regardless of the presence or not of anaemia. Importantly, the addition of red cell distribution width to the clinical risk model for the prediction of death or hospitalization for heart failure at 1 year had a significant integrated discrimination improvement of 33% (P<.001) and a net reclassification improvement of 10.3% (P=.001).
Red cell distribution width is an independent risk marker and adds prognostic information in outpatients with chronic heart failure. These findings suggest that this biological measurement should be included in the management of these patients. Full English text available from:www.revespcardiol.org.
红细胞分布宽度已成为心血管疾病新的预后生物标志物。其在慢性心力衰竭患者风险分层中的附加价值尚未明确。
共纳入698例连续性慢性心力衰竭门诊患者(中位年龄71岁[四分位间距,62 - 77岁],男性占63%,左心室射血分数40[14]%)。纳入时测量红细胞分布宽度,并记录临床、生化及超声心动图变量。中位随访期为2.5年[四分位间距1.2 - 3.7年]。
共211例患者死亡,206例因失代偿性心力衰竭需住院治疗。Kaplan - Meier分析显示,随着红细胞分布宽度四分位数增加,死亡及心力衰竭住院概率上升(对数秩检验,P <.001)。ROC分析确定红细胞分布宽度为15.4%是死亡风险显著升高(P <.001;风险比 = 2.63;95%置信区间,2.01 - 3.45)及心力衰竭住院风险显著升高(P <.001;风险比 = 2.37;95%置信区间,1.80 - 3.13)的最佳切点。该预测价值独立于其他协变量,且无论是否存在贫血。重要的是,将红细胞分布宽度加入到预测1年内心力衰竭死亡或住院的临床风险模型中,综合判别改善显著提高33%(P <.001),净重新分类改善提高10.3%(P =.001)。
红细胞分布宽度是慢性心力衰竭门诊患者的独立风险标志物,并可提供预后信息。这些发现提示该生物学指标应纳入这些患者的管理中。完整英文文本可从:www.revespcardiol.org获取。